New radioactive tracer could sharpen cancer detection
NCT ID NCT06471712
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new radioactive imaging agent called 18F-LNC1007 in 8 people—some healthy and some with a few small tumors. The goal was to see how the agent moves through the body, how much radiation it gives off, and whether it is safe. Participants received one injection and underwent PET/CT scans over several hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-LNC1007 injection (a radioactive imaging agent)
- What this could lead to
- If successful, this could lead to a new PET/CT imaging method to better detect and monitor small tumors.
- What could go wrong
- This is a very early, small study (8 people) focused on safety and imaging properties, not treatment. It may not lead to a widely used diagnostic tool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Precision Molecular Imaging & Theranostics (trading as Melbourne Theranostic Innovation Centre)
Melbourne, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults